Asunto(s)
Regulación Neoplásica de la Expresión Génica/genética , Linfocitos Infiltrantes de Tumor , Paraganglioma , Feocromocitoma , Macrófagos Asociados a Tumores , Neoplasias de las Glándulas Suprarrenales/genética , Neoplasias de las Glándulas Suprarrenales/inmunología , Neoplasias de las Glándulas Suprarrenales/patología , Algoritmos , Perfilación de la Expresión Génica/métodos , Mutación de Línea Germinal , Humanos , Inmunofenotipificación/métodos , Linfocitos Infiltrantes de Tumor/inmunología , Linfocitos Infiltrantes de Tumor/metabolismo , Aprendizaje Automático , Proteínas de Microfilamentos/genética , Tumores Neuroectodérmicos/genética , Tumores Neuroectodérmicos/inmunología , Tumores Neuroectodérmicos/patología , Paraganglioma/genética , Paraganglioma/inmunología , Paraganglioma/patología , Feocromocitoma/genética , Feocromocitoma/inmunología , Feocromocitoma/patología , Proteínas Proto-Oncogénicas c-ret/genética , Proteínas de Unión al ARN/genética , Análisis de Secuencia de ARN , Macrófagos Asociados a Tumores/inmunología , Macrófagos Asociados a Tumores/metabolismoAsunto(s)
Anticuerpos Monoclonales/metabolismo , Tumores Neuroectodérmicos/inmunología , Proteínas Recombinantes de Fusión/metabolismo , Animales , Anticuerpos Monoclonales/inmunología , Antígenos CD/inmunología , Antígenos de Neoplasias/inmunología , Moléculas de Adhesión Celular Neuronal/inmunología , Separación Celular , Ensayos Clínicos como Asunto , Reacciones Cruzadas , Ensayo de Inmunoadsorción Enzimática , Proteínas Fetales/inmunología , Citometría de Flujo , Gangliósidos/inmunología , Células HeLa , Humanos , Ratones , Tumores Neuroectodérmicos/tratamiento farmacológico , Tumores Neuroectodérmicos/metabolismo , Proteínas Recombinantes de Fusión/inmunologíaRESUMEN
PURPOSE: The aims of this study are to compare antitumor activities of two generations of GD3-specific chimeric antigen receptors (CAR) in human primary T lymphocytes in vitro and to evaluate the antitumor efficacy of using a combination of systemic infusion of interleukin-2 (IL2) and designer T cells to eradicate subcutaneous established GD3+ melanoma in nude mice. EXPERIMENTAL DESIGN: Antitumor activities were compared for two generations of designer T cells, the progenitor first-generation with immunoglobulin T-cell receptor (TCR) with Signal 1 and the second-generation designer T cells with Signal 1+2. Osmotic IL2 pumps were used to deliver the maximum tolerated dose of IL2 to enhance the antitumor effects of designer T cells on subcutaneous established melanoma in nude mice. RESULTS: Melanoma is associated with high expression of ganglioside GD3, which has been targeted with modest effect in antibody therapies. We previously showed that an anti-GD3 CAR (sFv-TCRzeta) will recruit T cells to target this non-T-dependent antigen, with potent killing of melanoma cells. Here, we report the addition of a CD28 costimulation domain to create a second-generation CAR, called Tandem for two signals. We show that this Tandem sFv-CD28/TCRzeta receptor on T cells confers advantages of improved cytokine secretion, cytotoxicity, proliferation, and clonal expansion on tumor contact versus the same CAR without costimulation. In an adoptive transfer model using established melanoma tumors, designer T cells with CD28 showed a 50% rate of complete remissions but only where IL2 was supplemented. CONCLUSIONS: As a reagent for clinical development, the second-generation product is shown to have superior properties to warrant its preference for clinical designer T-cell immunotherapy for melanoma and other tumors. Systemic IL2 was required for optimal activity in an established tumor model.
Asunto(s)
Antígenos CD28/inmunología , Gangliósidos/inmunología , Inmunoterapia Adoptiva/métodos , Melanoma Experimental/terapia , Receptores de Antígenos de Linfocitos T/inmunología , Animales , Western Blotting , Línea Celular Tumoral , Separación Celular , Quimera , Citocinas/biosíntesis , Femenino , Citometría de Flujo , Humanos , Interleucina-2 , Melanoma Experimental/inmunología , Ratones , Ratones Desnudos , Tumores Neuroectodérmicos/inmunología , Tumores Neuroectodérmicos/terapia , Linfocitos T/inmunología , Linfocitos T/trasplante , Transducción Genética , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Chemokines and chemokine receptors play an important role in immune homeostasis and surveillance. Altered or defective expression of chemokines and/or chemokine receptors could lead to a disease state including autoimmune disorder or cancer. Tumors from glioblastoma, melanoma, and neuroblastoma secrete high levels of chemokines that can promote tumor growth and progression or induce stromal cells present in the tumor microenvironment to produce cytokines or chemokines which, in turn, can regulate angiogenesis, tumor growth, and metastasis. On the other hand, chemokines secreted by tumor or stromal cells can also attract leukocytes such as dendritic cells, macrophages, neutrophils, and lymphocytes which may downmodulate tumor growth. New therapies that are aimed at limiting tumor growth and progression by attracting immune effector cells to the tumor site with chemokines may hold the key to the successful treatment of cancer, although this approach may be hampered by possible tumor growth-stimulating effects of chemokines.
Asunto(s)
Quimiocinas/inmunología , Tumores Neuroectodérmicos/inmunología , Animales , Movimiento Celular/inmunología , Humanos , Leucocitos/inmunología , Tumores Neuroectodérmicos/patología , Receptores de Quimiocina/inmunología , Células del EstromaRESUMEN
Chemokines and their receptors have emerged as pivotal regulators of tumour growth, progression, and metastasis. Here we review the current knowledge on chemokines and receptors likely involved in the development of metastasis of neuroectodermal tumours, with emphasis on neuroblastoma. In this respect, we discuss the controversial role of the CXCR4/CXCL12 axis in bone marrow localization of neuroblastoma cells. In addition, we focus on the ability of neuroblastoma-derived chemokines such as CCL2 and CX3CL1 to attract lymphoid cells to the tumour site. Finally, chemokine receptor and function in other neuroectodermal tumours of adulthood (i.e. melanoma and small cell lung cancer) are discussed.
Asunto(s)
Quimiocinas/inmunología , Metástasis de la Neoplasia/inmunología , Tumores Neuroectodérmicos/inmunología , Tumores Neuroectodérmicos/patología , Animales , Progresión de la Enfermedad , Humanos , Receptores de Quimiocina/inmunologíaRESUMEN
Although chemokines and their receptors were initially identified as regulators of cell trafficking during inflammation and immune response, they have emerged as crucial players in all stages of tumor development, primary growth, migration, angiogenesis, and establishment as metastases in distant target organs. Neuroectodermal tumors regroup neoplasms originating from the embryonic neural crest cells, which display clinical and biological similarities. These tumors are highly malignant and rapidly progressing diseases that disseminate to similar target organs such as bone marrow, bone, liver and lungs. There is increasing evidence that interaction of several chemokine receptors with corresponding chemokine ligands are implicated in the growth and invasive characteristics of these tumors. In this review we summarize the current knowledge on the role of CXCL12 chemokine and its CXCR4 and CXCR7 receptors in the progression and survival of neuroectodermal tumors, with particular emphasis on neuroblastoma, the most typical and enigmatic neuroectodermal childhood tumor.
Asunto(s)
Quimiocinas/inmunología , Tumores Neuroectodérmicos/inmunología , Receptores de Quimiocina/inmunología , Animales , Quimiocina CXCL12/inmunología , Humanos , Receptores CXCR/inmunología , Receptores CXCR4/inmunologíaRESUMEN
Neuroblastoma treatment with chimeric antidisialoganglioside GD2 Ab ch14.18 showed objective antitumor responses. Production of anti-idiotypic Abs (Ab2) against ch14.18 (Ab1) in some cases was positively correlated with a more favorable prognosis. According to Jerne's network theory, a subset of anti-idiotypic Abs (Ab2beta) carries an "internal image" of the Ag and induces Abs (Ab3) against the original Ag. The molecular origin of an anti-idiotypic Ab response in tumor patients was not investigated previously. To clone anti-idiotypic Abs, B cells of a ch14.18-treated neuroblastoma patient with Ab2 serum reactivity were used to construct Ab phage display libraries. After repeated biopannings on ch14.18 and its murine relative, anti-GD2 mAb 14G2a, we selected 40 highly specific clones. Sequence analysis revealed at least 10 of 40 clones with different Ig genes. Identities to putative germline genes ranged between 94.90 and 100% for V(H) and between 93.90 and 99.60% for V(L). An overall high rate of replacement mutations suggested a strong Ag-driven maturation of the anti-idiotypic Abs. Two clones that were analyzed further, GK2 and GK8, inhibited binding of ch14.18 to GD2 just as the patient's serum did. GK8 alone inhibited >80% of the patient's anti-idiotypic serum Abs in binding to ch14.18. Rabbits vaccinated with GK8 or GK2 (weaker) produced Ab3 against the original target Ag GD2. GK8 may be useful as a tumor vaccine for GD2-positive [corrected] tumors.
Asunto(s)
Anticuerpos Antiidiotipos/química , Anticuerpos Monoclonales/uso terapéutico , Vacunas contra el Cáncer/inmunología , Gangliósidos/inmunología , Recurrencia Local de Neoplasia/inmunología , Neuroblastoma/inmunología , Neuroblastoma/terapia , Tumores Neuroectodérmicos/prevención & control , Secuencia de Aminoácidos , Animales , Anticuerpos Antiidiotipos/biosíntesis , Anticuerpos Antiidiotipos/genética , Anticuerpos Monoclonales/química , Anticuerpos Monoclonales/metabolismo , Bacteriófago M13/genética , Sitios de Unión de Anticuerpos , Unión Competitiva , Vacunas contra el Cáncer/uso terapéutico , Clonación Molecular , Técnicas Químicas Combinatorias , Gangliósidos/metabolismo , Humanos , Región Variable de Inmunoglobulina/química , Región Variable de Inmunoglobulina/metabolismo , Cadenas kappa de Inmunoglobulina/química , Cadenas kappa de Inmunoglobulina/genética , Cadenas kappa de Inmunoglobulina/metabolismo , Cadenas lambda de Inmunoglobulina/química , Cadenas lambda de Inmunoglobulina/genética , Cadenas lambda de Inmunoglobulina/metabolismo , Ratones , Datos de Secuencia Molecular , Recurrencia Local de Neoplasia/terapia , Tumores Neuroectodérmicos/inmunología , Biblioteca de PéptidosAsunto(s)
Candidiasis/complicaciones , Candidiasis/diagnóstico , Epiglotitis/complicaciones , Infecciones Oportunistas/complicaciones , Antibacterianos/uso terapéutico , Antifúngicos/uso terapéutico , Candidiasis/tratamiento farmacológico , Preescolar , Epiglotitis/tratamiento farmacológico , Epiglotitis/microbiología , Femenino , Estudios de Seguimiento , Humanos , Huésped Inmunocomprometido , Laringoscopía , Tumores Neuroectodérmicos/inmunología , Tumores Neuroectodérmicos/terapia , Infecciones Oportunistas/diagnóstico , Infecciones Oportunistas/tratamiento farmacológico , Resultado del TratamientoRESUMEN
The serum of a patient with subacute cerebellar dysfunction was used to probe a cDNA expression library and isolate two genes: Zic1 (zinc-finger of the cerebellum) and Zic4. The patient had intrathecal synthesis of Zic antibodies, suggesting that the Zic proteins were autoantigens of the neurologic disorder. The Zic proteins are involved in cerebellar development and are reported as being preferentially expressed by medulloblastomas. It was found that the expression of Zic proteins is enriched in, but not limited to, medulloblastomas and primitive neuroectodermal tumors.
Asunto(s)
Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/patología , Enfermedades Cerebelosas/patología , Cerebelo/patología , Degeneración Nerviosa/patología , Dedos de Zinc/inmunología , Anciano , Autoanticuerpos/análisis , Autoanticuerpos/líquido cefalorraquídeo , Autoanticuerpos/inmunología , Western Blotting , Neoplasias Cerebelosas/inmunología , Neoplasias Cerebelosas/patología , ADN Complementario/genética , Humanos , Inmunohistoquímica , Imagen por Resonancia Magnética , Masculino , Meduloblastoma/inmunología , Meduloblastoma/patología , Tumores Neuroectodérmicos/inmunología , Tumores Neuroectodérmicos/patologíaRESUMEN
Dendritic cell (DC) development and function is critical in the initiation phase of any antigen-specific immune response against tumours. Impaired function of DC is one explanation as to how tumours escape immunosurveillance. In the presence of various soluble tumour-related factors DC precursors lose their ability to differentiate into mature DC and to activate T cells. Gangliosides are glycosphingolipids shed by tumours of neuroectodermal origin such as melanoma and neuroblastoma. In this investigation we address the question of whether gangliosides suppress the development and function of monocyte-derived DC in vitro. In the presence of gangliosides, the monocytic DC precursors showed increased adherence, cell spreading and a reduced number of dendrites. The expression of MHC class II molecules, co-stimulatory molecules and the GM-CSF receptor (CD116) on the ganglioside-treated DC was significantly reduced. Furthermore, the function of ganglioside-treated DC was impaired as observed in endocytosis, chemotactic and T cell proliferation assays. In contrast to monocytic DC precursors, mature DC were unaffected even when higher doses of gangliosides were added to the culture. With regard to their carbohydrate structure, five different gangliosides (GM2, GM3, GD2, GD3, GT1b), which are typically shed by melanoma and neuroblastoma, were tested for their ability to suppress DC development and function. Suppression was induced by GM2, but not by the other gangliosides. These data suggest that certain gangliosides impair DC precursors, implying a possible mechanism for tumour escape.
Asunto(s)
Gangliósidos/farmacología , Monocitos/citología , Tumores Neuroectodérmicos/inmunología , Escape del Tumor , Adhesión Celular/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Células Cultivadas , Quimiotaxis de Leucocito/efectos de los fármacos , Células Dendríticas/citología , Células Dendríticas/efectos de los fármacos , Células Dendríticas/inmunología , Endocitosis/efectos de los fármacos , Citometría de Flujo , Gangliósido G(M2)/farmacología , Antígenos HLA-D/inmunología , Humanos , Inmunofenotipificación , Prueba de Cultivo Mixto de Linfocitos , Melanoma/inmunología , Monocitos/efectos de los fármacos , Monocitos/inmunología , Neuroblastoma/inmunologíaRESUMEN
OBJECTIVE: To estimate different proteins and immunoglobulins as humoral immune response in patients with intracranial tumours. METHODS: Cellulose acetate membrane electrophoresis for estimation of different proteins and radialimmunodiffusion (RID) for measurement of serum and CSF immunoglobulins were used. RESULTS: Thirty seven patients with different types of tumours showed increase in serum alpha II globulin, significant decrease of IgG, in patients when compared with controls, significant decrease of IgG in malignant tumours compared with benign tumours. CSF albumin, gamma globulin, immunoglobulins G,A,and M were increased. CONCLUSION: Alpha II globulin, steroid therapy and active neoplasia may be responsible for decreased serum immunoglobulins, while raised gamma globulin and immunoglobulins with intact BBB indicates capability of CNS to produce immunoglobulins.
Asunto(s)
Adenoma/inmunología , Neoplasias Encefálicas/inmunología , Inmunoglobulinas/sangre , Inmunoglobulinas/líquido cefalorraquídeo , Tumores Neuroectodérmicos/inmunología , Adulto , Barrera Hematoencefálica/inmunología , Proteínas del Líquido Cefalorraquídeo/análisis , Femenino , Humanos , Inmunodifusión , MasculinoRESUMEN
BACKGROUND: Adjuvant interleukin-2 (IL-2) therapy after stem cell transplantation can improve the prognosis of patients with Ewing tumors. This has been attributed to stimulation of the immune system and its antineoplastic activity, thus eliminating minimal residual disease. As the side effects of systemic IL-2 limit the dosage, attempts have been made to locally augment the concentration of IL-2 in the proximity of the tumor. To achieve this, fibroblasts and/or tumor cells can be genetically modified to secrete IL-2 and then be injected to generate tumor immunogen. PROCEDURE: In a preliminary clinical trial we assessed whether the administration of transgenic IL-2-secreting fibroblasts was feasible without major toxicity and whether it had any effect regarding the activation of the immune system. We treated an 11-year-old boy with a peripheral neuroectodermal tumor of the left neck in fourth relapse, who was refractory to all available therapy. We transfected fibroblasts of the patient with an IL-2 gene expression vector using a cationic liposome reagent. In 51Cr cytotoxicity assays we obtained lysis of this patient's tumor cells by IL-2-stimulated mononuclear cells (MNCs). Under CT-guidance we intratumorally injected IL-2 transgenic autologous fibroblasts. RESULTS: We observed no local or systemic toxicity. In addition, we found a rise in the CD3+CD56+ lymphocyte population, previously described as cytokine-induced killer cells. No other hematological parameter changed significantly. CONCLUSIONS: Our data suggest that the intratumoral injection of transgenic IL-2-secreting fibroblasts is feasible without major toxicity and may lead to an increase in CD3+CD56+ cells.
Asunto(s)
Complejo CD3 , Antígeno CD56 , Fibroblastos , Neoplasias de Cabeza y Cuello/terapia , Interleucina-2/metabolismo , Células Asesinas Naturales/metabolismo , Tumores Neuroectodérmicos/terapia , Niño , Terapia Genética , Neoplasias de Cabeza y Cuello/inmunología , Humanos , Inyecciones Intralesiones , Masculino , Tumores Neuroectodérmicos/inmunología , Transfección , Células Tumorales CultivadasRESUMEN
OBJECTIVE: To determine whether a heterogeneous collection of salivary gland tumors shared common antigenic characteristics and growth patterns in tissue culture. DESIGN: Cell cultures were derived from benign and malignant salivary gland neoplasms, cultured conservatively, and serially analyzed for epithelial, myoepithelial, and neuroectodermal antigens. SUBJECTS: Nineteen samples reflecting the spectrum of salivary tumor pathologic characteristics were established in tissue culture. Most were derived from benign pleomorphic adenomas, and several were from carcinomas, including carcinoma ex pleomorphic adenoma, and mucoepidermoid and adenoid cystic carcinoma. RESULTS: All cultures were epithelial as determined by morphologic and antigenic examination, using antibodies for cytokeratin. The phenotype of cells derived from benign tumors, especially the pleomorphic adenomas, resembled those in the original neoplasm. Those from carcinomas were similar, with less differentiated characteristics. Manipulation of growth conditions altered the phenotypes shown in culture. Some cultures contained cells expressing vascular smooth-muscle actin and glial fibrillary acidic protein or nestin. CONCLUSIONS: This model cell system containing proliferative cells from several tumor types is consistent with a stem-cell theory of salivary gland tumor origin. Our data were not consistent with the bicellular or multicellular theory. We hypothesize a neuroectodermal origin for this group of apparently heterogeneous tumors. These cultured cells will be valuable for in-depth investigation of the loss of proliferation controls in benign and malignant tumors of the salivary gland.
Asunto(s)
Antígenos de Neoplasias/análisis , Tumores Neuroectodérmicos/inmunología , Neoplasias de las Glándulas Salivales/inmunología , Glándulas Salivales/inmunología , Anticuerpos Monoclonales , División Celular , Proteína Ácida Fibrilar de la Glía/ultraestructura , Humanos , Inmunohistoquímica , Neoplasias de las Glándulas Salivales/patología , Neoplasias de las Glándulas Salivales/ultraestructura , Glándulas Salivales/patología , Glándulas Salivales/ultraestructura , Células Tumorales CultivadasRESUMEN
The reactivity of a mAb (M16) raised against a small cell lung carcinoma line is described. M16 identifies a surface antigen expressed on cells of neuroectodermal origin following activation, as well as neoplastic transformation. M16 antigen expression is increased on retinoblastoma and neuroblastoma cell lines upon 'in vitro' stimulation and it is induced 'in vivo' on glial cells activated following brain injury. Furthermore, glial tumors show levels of M16 molecule expression increasing with the degree of malignancy, and in a retinoblastoma cell line, the expression of M16 was inversely related to the level of HLA-Class I and N-CAM antigens. The M16 antigen may represent a marker of both activation and neoplastic progression for neuroectodermal cells.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Antígenos de Neoplasias/análisis , Antígenos de Superficie/análisis , Carcinoma de Células Pequeñas/inmunología , Neoplasias Pulmonares/inmunología , Tumores Neuroectodérmicos/inmunología , Animales , Moléculas de Adhesión Celular Neuronal/análisis , Línea Celular , Transformación Celular Neoplásica , Ratones , Retinoblastoma/inmunologíaRESUMEN
Fusion of myeloma (P3X63-Ag 8.653) cells with spleen cells from BALB/c mice immunized with human neuroblastoma (SK-N-SH) cells yielded a hybridoma clone, referred to as 3XB7, with a unique pattern of reactivity to malignant neuroectodermal tumors except gliomas of low-grade malignancy. Indirect immunofluorescence staining under different conditions and Western blot analysis indicate that the 3XB7 MAb recognizes an intracellular cytoskeletal protein of M(r) 52K. Immunohistochemical studies with cryostat and paraffin-embedded sections from tumor biopsies revealed that the 3XB7 MAb specifically recognizes malignant neuroectodermal tumors and reacts negatively with other epithelial and mesenchymal tumors, e.g., carcinomas, lymphomas, and sarcomas as well as with normal adult and fetal brain tissues. Negative reaction was also observed with other small round cell tumors of childhood. Thus the 3XB7 antigen can be used for diagnosis of all stages of neuroblastomas, and its specific expression in gliomas with high-grade malignancy (grades III and IV) confer on it additional prognostic value.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Anticuerpos Antineoplásicos/inmunología , Antígenos de Neoplasias/inmunología , Proteínas del Citoesqueleto/inmunología , Proteínas de Neoplasias/inmunología , Tumores Neuroectodérmicos/inmunología , Adulto , Animales , Especificidad de Anticuerpos , Encéfalo/embriología , Encéfalo/inmunología , Neoplasias Encefálicas/inmunología , Niño , Técnica del Anticuerpo Fluorescente , Ganglios Simpáticos/inmunología , Humanos , Hibridomas/inmunología , Linfoma/inmunología , Ratones , Ratones Endogámicos BALB C , Tumores Neuroectodérmicos/clasificación , Especificidad de Órganos , Células Tumorales Cultivadas , Vísceras/inmunologíaRESUMEN
Melanomas from different patients have been shown to express shared tumor antigens, which can be recognized in the context of the appropriate MHC class I molecules by cytolytic T cells. To determine if T-cell-defined melanoma antigens are expressed on other tumors of neuroectodermal origin, four melanoma-specific cytotoxic T lymphocyte (CTL) cultures derived from tumor-infiltrating lymphocytes (TIL) were tested for lysis of a panel of 23 HLA-A2+ neuroectodermal tumor cell lines of various histologies, including retinoblastoma (1), neuroblastoma (8), neuroepithelioma (6), astrocytoma (2), neuroglioma (1), and Ewing's sarcoma (5). Low expression of MHC class I and/or ICAM-1 molecules was found on 22 of 23 neuroectodermal tumor lines, and could be enhanced by treatment with interferon gamma (IFN gamma). Following IFN gamma treatment, three Ewing's sarcoma lines were lysed by at least one melanoma TIL culture, and levels of lysis were comparable to melanoma lysis by these TIL. Lysis could be inhibited by monoclonal antibodies directed against MHC class I molecules and against CD3, indicating specific immune recognition of tumor-associated antigens. None of the other neuroectodermal tumors tested were lysed by TIL, but they could be lysed by non-MHC-restricted lymphokine-activated killer cells. This demonstration of immunological cross-reactivity between melanomas and Ewing's sarcomas, two tumors of distinct histological types with a common embryonic origin, has implications for the developmental nature of these CTL-defined tumor antigens. It also raises the possibility that specific antitumor immunotherapies, such as vaccines, may be reactive against more than one form of cancer.
Asunto(s)
Antígenos de Neoplasias/inmunología , Melanoma/inmunología , Tumores Neuroectodérmicos/inmunología , Linfocitos T Citotóxicos/inmunología , Animales , Anticuerpos Antineoplásicos/inmunología , Citotoxicidad Inmunológica , Epítopos , Femenino , Antígeno HLA-A2/inmunología , Antígenos de Histocompatibilidad Clase I/inmunología , Humanos , Interferón gamma/farmacología , Linfocitos Infiltrantes de Tumor/inmunología , Ratones , Ratones Endogámicos BALB C , Cresta Neural/inmunología , Fenotipo , Receptores de Antígenos de Linfocitos T/inmunología , Sarcoma de Ewing/inmunología , Células Tumorales CultivadasRESUMEN
Chemotactic activity of granulocytes attracted by tumor cells loaded either with anti-ganglioside monoclonal antibodies (mAb) or with antibody-glucose oxidase conjugates (mAb-GO) was investigated. The melanoma cell line SK-Mel-28 which expresses the ganglioside GD3 at high density as well as the neuroectodermal cell line SK-N-LO which expresses GD2 were used for the experiments. In the presence of 50% human AB-serum, antibody-loaded tumor cells induced chemotactic activity on granulocytes, probably due to the generation of C3a/C5a which could be detected in serum incubated with anti-GD3 loaded SK-Mel-28 cells. Both compounds could also be detected in vivo in the plasma of patients suffering from neuroblastoma during therapy with anti-GD2 antibodies. In another set of experiments mAb-GO conjugates generating high amounts of H2O2 in the presence of glucose were bound to these tumor cells. A significant lipid peroxidation could be observed in the simultaneous presence of iron and ascorbate. The lipid peroxidation products were measured as thiobarbituric acid-reactive substances (TBARS) and were also shown to induce chemotactic effects on granulocytes.
Asunto(s)
Factores Quimiotácticos/biosíntesis , Granulocitos/inmunología , Sistema del Grupo Sanguíneo ABO , Anticuerpos Monoclonales , Quimiotaxis , Complemento C3a/análisis , Complemento C5a/análisis , Gangliósidos/inmunología , Glucosa Oxidasa/inmunología , Humanos , Peróxido de Hidrógeno/metabolismo , Peroxidación de Lípido , Melanoma/inmunología , Melanoma/patología , Tumores Neuroectodérmicos/inmunología , Tumores Neuroectodérmicos/patología , Células Tumorales CultivadasRESUMEN
Gangliosides are known to be suitable targets for immune attack against cancer but they are poorly immunogenic. Active immunization with ganglioside/BCG or liposome vaccines results in moderate titer IgM antibody responses of short duration. Covalent attachment of poorly immunogenic antigens to immunogenic proteins is a potent method for inducing an IgG antibody response. GD3, a dominant ganglioside on malignant melanoma, was modified by ozone cleavage of the double bond in the ceramide backbone, an aldehyde group introduced and used for coupling via reductive amination to epsilon-amino-lysyl groups of proteins. Utilizing this method, GD3 conjugates were constructed with: 1. Synthetic multiple antigenic peptide (MAP) constructs expressing 4 repeats of a malaria T-cell epitope; 2. Outer membrane proteins (OMP) of Neisseria meningitidis; 3. Cationized bovine serum albumin; 4. Keyhole limpet hemocyanin (KLH); and 5. Polylysine. In addition, conjugates containing only the GD3 oligosaccharide were synthesized. All constructs were tested for antigenicity using anti-GD3 antibody R24, and for immunogenicity in mice. Serum antibody levels were analyzed by ELISA and immune thin-layer chromatography. Results in the mouse show a significant improvement in the IgM antibody response and a consistent IgG response against GD3 using GD3-KLH conjugates. Other carrier proteins and the use of GD3 oligosaccharide were significantly less effective. If improved immunogenicity and clinical benefit with conjugate vaccines can be demonstrated in patients with melanoma, this approach may be applicable to patients with other tumors of neuroectodermal origin, including gliomas, glioblastomas, astrocytomas, and neuroblastomas.